Compare Citius Pharmaceuticals Inc (CTXR) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ServiceNow Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while ServiceNow Inc trades at $125.65 (market cap $129.11B). The key difference: ServiceNow Inc is far larger — about 6893.2× Citius Pharmaceuticals Inc's market cap, and ServiceNow Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | NOW | |
|---|---|---|
Market Cap | $18.73M | $129.11B |
Sector | Health | Technology |
52-Week High | $1.82 | $192.23 |
52-Week Low | $0.48 | $83.00 |
Enterprise Value | $14.95M | $132.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
ServiceNow (NOW) trades at $127.54, up 2.13% with strong technical momentum. The stock shows robust fundamentals with 2025 revenue reaching $13.28B and net income of $1.75B, though valuation ratios remain elevated (P/E 78.05). Recent earnings performance has been mixed with Q2 2026 beating expectations but Q1 missing. Technical indicators show bullish moving averages but overbought RSI signals. The company maintains strong analyst support with 87% buy ratings and a $138.26 consensus target.
ServiceNow presents a compelling growth story with AI-driven expansion opportunities, though premium valuation requires careful risk assessment. Key risks include competitive pressures in enterprise software and execution challenges in maintaining high growth rates. The stock's current technical overbought condition suggests potential near-term consolidation before further upside potential toward analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
